Paul H. Cottu, MD, Institut Curie Paris, France
Ribociclib Combined with Endocrine Neoadjuvant Therapy Delivers a Precision-Intensification Strategy for High-Risk ER+/HER2- Breast Cancer Patients!
Paul H. Cottu, MD, Institut Curie Paris, France
Ribociclib Combined with Endocrine Neoadjuvant Therapy Delivers a Precision-Intensification Strategy for High-Risk ER+/HER2- Breast Cancer Patients!